copanlisib hydrochloride

Drug Overview

Copanlisib hydrochloride is an FDA-approved targeted therapy used in the treatment of certain types of lymphoma. It belongs to a class of precision oncology agents known as PI3K inhibitors, designed to interfere with specific molecular signals that cancer cells depend on for growth and survival. Unlike traditional chemotherapy, which affects both healthy and cancerous cells broadly, copanlisib is engineered to act on defined biological targets within tumor cells, making it a true smart drug in the field of modern oncology.

Developed by Bayer, copanlisib hydrochloride is marketed under the brand name Aliqopa and represents a meaningful treatment advance for patients with relapsed follicular lymphoma who have already received at least two prior lines of systemic therapy. It is administered intravenously in a clinical setting under the supervision of a qualified oncology team.

• Generic Name: Copanlisib hydrochloride
• US Brand Names: Aliqopa
• Drug Class: Phosphatidylinositol 3-Kinase (PI3K) Inhibitor; Targeted Therapy; Kinase Inhibitor; Antineoplastic Agent
• Route of Administration: Intravenous (IV) Infusion
• FDA Approval Status: FDA-approved. Granted accelerated approval in September 2017 for the treatment of relapsed follicular lymphoma in adults who have received at least two prior systemic therapies. Continued approval may depend on confirmatory trial results

What Is It and How Does It Work? (Mechanism of Action)

Copanlisib hydrochloride is a targeted therapy that works by blocking a critical signaling network that many cancer cells rely on to grow, divide, and survive. To understand its mechanism, it is important to first understand the PI3K pathway and why it matters in cancer biology.

Phosphatidylinositol 3-kinase, commonly referred to as PI3K, is a family of enzymes that act as key communicators inside cells. When activated by external growth signals, PI3K enzymes trigger a cascade of downstream molecular events involving proteins such as AKT and mTOR. This PI3K/AKT/mTOR signaling pathway regulates essential cellular functions including cell growth, proliferation, survival, and metabolism. In many cancers, particularly B-cell lymphomas, this pathway is abnormally and continuously activated due to mutations or overexpression of PI3K subunits, essentially telling cancer cells to keep growing without the normal biological checks that would otherwise stop them.

Copanlisib is a pan-Class I PI3K inhibitor, meaning it inhibits multiple isoforms of the PI3K enzyme, with particularly strong activity against the PI3K-alpha and PI3K-delta isoforms. PI3K-delta is predominantly expressed in B-cells and plays a central role in the proliferation and survival of malignant B-cell populations in lymphomas. PI3K-alpha, while more broadly expressed, is frequently mutated and overactivated in solid tumors and certain hematologic malignancies. By binding to and blocking both of these isoforms, copanlisib simultaneously disrupts two important branches of the PI3K signaling pathway.

When copanlisib inhibits PI3K, it prevents the production of phosphatidylinositol-3,4,5-trisphosphate (PIP3), a key second messenger molecule that is necessary to activate AKT. Without active AKT, the downstream mTOR complex is also suppressed, halting the molecular instructions that drive cancer cell proliferation. The result is induction of apoptosis in tumor cells and inhibition of their ability to multiply. This dual isoform inhibition distinguishes copanlisib from some other PI3K inhibitors and contributes to its observed activity in follicular lymphoma.

FDA Approved Clinical Indications

Copanlisib hydrochloride has received FDA approval for a specific oncological indication. It does not currently have approved non-oncological uses.

Oncological Uses (FDA-Approved):

• Relapsed follicular lymphoma in adult patients who have received at least two prior systemic therapies, approved under the FDA accelerated approval pathway based on overall response rate data

Oncological Uses (Investigational):

• Marginal zone lymphoma, studied in clinical trials as part of expanded indications for PI3K inhibition in indolent B-cell lymphomas
• Diffuse large B-cell lymphoma, explored in combination regimens in early-phase trials
• Solid tumors including endometrial cancer and non-small cell lung cancer, investigated in early-phase studies based on PI3K-alpha mutation prevalence

Non-Oncological Uses:

• There are no currently approved or widely investigated non-oncological indications for copanlisib hydrochloride

Dosage and Administration Protocols

Copanlisib is administered intravenously in a clinical oncology setting. It follows an intermittent dosing schedule designed to balance therapeutic efficacy with tolerability, particularly with respect to metabolic side effects such as hyperglycemia and hypertension.

Clinical Efficacy and Research Results

Copanlisib received its FDA accelerated approval based on results from the CHRONOS-1 trial, a pivotal single-arm Phase 2 study that evaluated the drug in patients with relapsed or refractory indolent non-Hodgkin lymphoma who had received at least two prior lines of therapy. In the follicular lymphoma subgroup, copanlisib demonstrated a meaningful overall response rate, with a significant proportion of patients achieving either complete or partial tumor responses. The median duration of response observed in this trial supported the clinical relevance of the drug in this heavily pre-treated population.

Subsequent and ongoing research between 2020 and 2025 has explored copanlisib in broader clinical contexts. The CHRONOS-3 trial investigated copanlisib in combination with rituximab in patients with relapsed indolent non-Hodgkin lymphoma. Results demonstrated a statistically significant improvement in progression-free survival for the combination arm compared to rituximab plus placebo, providing important evidence supporting the use of copanlisib as part of combination regimens. 

Safety Profile and Side Effects

There is no FDA Black Box Warning specific to copanlisib hydrochloride. However, clinicians should be aware that serious and clinically significant adverse effects have been documented, particularly metabolic and cardiovascular effects that require proactive monitoring and management throughout the treatment course.

Common Side Effects (greater than 10%):

• Hyperglycemia, a transient but significant rise in blood sugar levels, typically occurring on the day of infusion and resolving between doses
• Hypertension, a transient rise in blood pressure closely associated with infusion days
• Fatigue and generalized weakness reported frequently across trial populations
• Diarrhea, observed commonly particularly in combination regimens
• Nausea, generally mild to moderate in severity
• Decreased white blood cell count (leukopenia and neutropenia), increasing infection susceptibility
• Decreased platelet count (thrombocytopenia), increasing bleeding risk
• Anemia, observed across multiple study populations

Serious Adverse Events:

• Severe hyperglycemia requiring clinical intervention, particularly in patients with pre-existing diabetes or impaired glucose tolerance
• Severe hypertension requiring antihypertensive therapy or dose interruption
• Serious infections including pneumonia and opportunistic infections secondary to immunosuppression
• Non-infectious pneumonitis, an inflammatory lung condition requiring corticosteroid treatment and potential drug discontinuation
• Severe cutaneous reactions including rare but serious skin toxicity
• Embryo-fetal toxicity; copanlisib can cause fetal harm and must not be used during pregnancy

Management Strategies:

Blood glucose should be measured before each infusion and approximately one hour after infusion completion. If fasting blood glucose exceeds established thresholds, dose modifications or delays should be applied per prescribing guidelines. Blood pressure must be monitored before and throughout each infusion session. Antihypertensive therapy should be optimized before treatment begins, and infusions should be withheld if blood pressure is severely elevated at the time of administration. Research Areas

Copanlisib does not currently occupy a defined role in stem cell transplantation or regenerative medicine. However, it is the subject of several active and clinically meaningful research directions within modern oncology. The most prominent area involves combination strategies pairing copanlisib with anti-CD20 monoclonal antibodies such as rituximab, based on the complementary mechanisms of PI3K inhibition and B-cell surface antigen targeting. Results from the CHRONOS-3 trial have already provided clinical validation for this approach. Investigators are also exploring copanlisib in combination with immune checkpoint inhibitors, hypothesizing that PI3K pathway suppression in the tumor microenvironment may enhance T-cell mediated antitumor immunity and improve responses to PD-1 or PD-L1 blockade. Additionally, research into PI3K-alpha mutations in solid tumors continues to expand the potential application of copanlisib beyond lymphoma, with early-phase trials in endometrial and lung cancer informing future development directions.

Patient Management and Practical Recommendations

Pre-Treatment Tests to Be Performed:

• Fasting blood glucose measurement to establish a metabolic baseline and identify pre-existing diabetes or glucose intolerance
• Blood pressure assessment to ensure hypertension is optimally managed before the first infusion
• Complete blood count to document baseline white blood cell, platelet, and hemoglobin levels
• Comprehensive metabolic panel including liver and kidney function tests
• Baseline chest imaging to document pulmonary status prior to treatment initiation
• Serum pregnancy test for all women of childbearing potential; effective contraception must be confirmed
• Hepatitis B virus screening, as immunosuppression may reactivate latent hepatitis B infection

Precautions During Treatment:

• Blood glucose and blood pressure must be measured before and after every infusion session without exception
• Infusions should be withheld if blood pressure or glucose values exceed protocol-specified thresholds at the time of scheduled administration
• Patients should be observed during and for a period following each infusion for signs of acute adverse reactions
• Patients with diabetes require particularly close glucose management coordination with their treating endocrinologist or primary care physician
• Any respiratory symptoms arising between cycles should be reported immediately and investigated for pneumonitis

Do’s and Don’ts:

• Inform your oncologist about all medications you are taking, including antihypertensives, antidiabetic drugs, and any herbal supplements
• Monitor your blood pressure at home between infusion sessions if your physician recommends it
• Attend every scheduled infusion, laboratory test, and follow-up appointment without interruption
• Report any new cough, shortness of breath, or chest discomfort to your medical team immediately
• Use effective contraception throughout treatment and for at least one month after the final dose
• Do not eat a high-carbohydrate meal before your infusion day as this may worsen treatment-related blood sugar elevation
• Do not take new over-the-counter medications or supplements without first consulting your oncologist
• Do not ignore elevated blood pressure readings on infusion days; always notify your clinical team before the infusion begins
• Do not breastfeed during treatment or for any period recommended by your physician following the last dose

Legal Disclaimer

The information presented in this guide is intended solely for educational and informational purposes and does not constitute medical advice, a clinical diagnosis, or a formal treatment recommendation. While copanlisib hydrochloride has received FDA accelerated approval for a specific oncological indication, all treatment decisions must be made exclusively by a qualified and licensed oncologist or healthcare professional, in full consideration of the patient’s individual medical history, current clinical condition, and the regulatory framework applicable in their country of residence.